Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 20, 2024

Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes

Assembly Biosciences has received an investment from Gilead Sciences, comprising a $20.1m equity investment and $10m in accelerated funding, to propel the clinical development of new antiviral therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV).

Continue
The funding is said to propel the clinical development of new antiviral therapies. Credit: National Institute of Allergy and Infectious Diseases on Unsplash.
December 19, 2024

Agios announces EC’s positive decision for sickle cell disease therapy designation

The oral, PK activator is intended to treat sickle cell disease. Credit: danilo.alvesd on Unsplash.
December 18, 2024

Akamis secures funds to advance cancer therapy through study

The investment will support the advancement of NG-350A through a Phase Ib clinical proof-of-concept study. Credit: National Cancer Institute on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Candid partners with EpimAb to develop T-cell engager candidates
  2. Sanofi’s multiple sclerosis therapy gains breakthrough therapy status from FDA
  3. Tanner-Agenus partner for expanded access to immunotherapies for cancer patients
  4. ProQR expands partnership with RSRT to advance Rett Syndrome therapy
  5. Orthogon secures funding to boost BK virus treatments for transplant patients

PRESS RELEASES

Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation